The protective role of oxcarbazepine on neurones in mood disorder
- Conditions
- Health Condition 1: null- 25 patients with bipolar mania will be included in the study.
- Registration Number
- CTRI/2017/11/010516
- Lead Sponsor
- DR RITUPARNA MAITI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
•All patients with the diagnosis of bipolar affective disorder (by ICD-10 DCR) current episode mania without psychotic symptoms
•Patients aged 18-45 years, of either sex.
•Patientswith baseline score >20 on the Young Mania Rating Scale (YMRS).
•Patients who had not taken any treatment for at least 4 weeks before inclusion.
•Patients with bipolar disorder (by ICD-10 DCR) presenting during depressive/euthymic/mixed episode.
•Patients who are already under treatment for the presenting conditions.
•Rapid cycling in the past 12 months.
•Previous history of refractoriness to carbazepine or oxcarbazepine.
•Patients with comorbid substance abuse or history of organicity
•Pregnant and nursing women, patients with history ofmajor medical or neurological illness.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum BDNFTimepoint: Baseline and 4 weeks
- Secondary Outcome Measures
Name Time Method Correlation between YMRS (Young Mania Rating Scale) and Serum BDNFTimepoint: Baseline and 4 weeks